Nienke G. Lankheet
Enschede, OV, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study.
Journal: Clinical lung cancer
Published: December 16, 2024
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview.
Journal: The Lancet. Oncology
Published: February 23, 2022
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Journal: Anti-cancer drugs
Published: February 15, 2021
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
Journal: The Lancet. Oncology
Published: December 12, 2018
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Journal: British journal of clinical pharmacology
Published: February 06, 2017
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Journal: Therapeutic drug monitoring
Published: December 06, 2013
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Journal: Leukemia research
Published: May 28, 2013
Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.
Journal: Therapeutic drug monitoring
Published: March 19, 2013
The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.
Journal: European journal of clinical pharmacology
Published: January 20, 2013
Last Updated: 09/26/2026